Major pharmaceutical companies are investing heavily in nuclear medicine theranostics, including mass-market television and print campaigns that highlight the precision tools we provide to physicians. The number of clinical trials has reached unprecedented levels, and the current demands and expected growth are straining the system. The complexity of what is needed is increasing, including the expertise and resources required. Companies and outside organizations see huge potential in theranostics but also note challenges to reaching its full potential. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has been at the forefront of advancing the field of theranostics through initiatives and programs that have accelerated both clinical practice and research including the creation of Centers of Excellence, establishment of a dedicated Therapy Clinical Trials Network, development of accreditation in partnership with the Intersocietal Accreditation Commission, and the planning and hosting of the annual Therapeutics Conference, recently renamed the Theranostics Conference. These efforts reflect SNMMI's vision to meet the growing demand for theranostics while also tackling challenges such as workforce development, supply shortages, and facility infrastructure-all with a focus on keeping care patient-centered. To broaden its perspective on the challenges and to develop practical solutions with broad support, the SNMMI took a bold step and invited participants from outside of the society to join the discussion. The SNMMI held a stakeholder summit on May 1-3, 2025, where more than 100 stakeholders came together to develop a path forward to ensure that the enormous potential for theranostics for patients could be realized. Herein is a synopsis of that summit.
Cathy S. Cutler (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: